Company intelligence / Profile preview

ARTham Therapeutics, Inc.

Tokyo/Bunkyo-ku, Tokyo Prefecture, Japanarthamtherapeutics.com ↗

Ownership: Private
Employees: ~6
Development stage: Phase 3

Overview

ARTham Therapeutics has advanced its lead program ART‑001, a PI3Kα inhibitor for vascular malformations, into Phase 3 clinical trials. Another program targeting PDE4 for NASH has reached Phase 1. The company’s pipeline also includes an underactive bladder therapy in preclinical or pending status. The company was acquired by Kaken Pharmaceutical in November 2021 and operates with a virtual R&D model focused on disease-modifying drugs for unmet medical needs.

Therapeutic areas: GastroenterologyCardiovascularDermatologyNephrology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

camostat mesilate

Phase 3

Indications: COVID-19

Partnerships

Takeda PharmaceuticalOita Venture CapitalKaken Pharmaceutical

Beyond the preview

Go deeper on ARTham Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARTham Therapeutics, Inc..

Explore the full profile